FDA Approves Ziihera

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in
First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Click here to learn more.